Ardelyx, Inc.

DB:41X Stock Report

Market Cap: €1.0b

Ardelyx Valuation

Is 41X undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 41X when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 41X (€4.2) is trading below our estimate of fair value (€65.85)

Significantly Below Fair Value: 41X is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 41X?

Key metric: As 41X is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 41X. This is calculated by dividing 41X's market cap by their current revenue.
What is 41X's PS Ratio?
PS Ratio4.4x
SalesUS$251.85m
Market CapUS$1.07b

Price to Sales Ratio vs Peers

How does 41X's PS Ratio compare to its peers?

The above table shows the PS ratio for 41X vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.3x
BIO3 Biotest
1.3x-4.1%€1.3b
FYB Formycon
13.6x32.5%€826.3m
MOR MorphoSys
10.2xn/a€2.6b
2INV 2invest
7.9xn/a€60.9m
41X Ardelyx
4.4x25.6%€1.1b

Price-To-Sales vs Peers: 41X is good value based on its Price-To-Sales Ratio (4.4x) compared to the peer average (8.3x).

Price to Sales Ratio vs Industry

How does 41X's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.3x-4.1%US$1.42b
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
41X 4.4xIndustry Avg. 7.9xNo. of Companies7PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 41X is good value based on its Price-To-Sales Ratio (4.4x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 41X's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

41X PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.4x
Fair PS Ratio5.5x

Price-To-Sales vs Fair Ratio: 41X is good value based on its Price-To-Sales Ratio (4.4x) compared to the estimated Fair Price-To-Sales Ratio (5.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 41X forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€4.20
€10.15
+141.5%
26.1%€14.27€5.23n/a9
Nov ’25€5.48
€10.61
+93.7%
17.9%€13.84€6.46n/a9
Oct ’25€6.10
€10.29
+68.6%
17.9%€13.69€6.39n/a9
Sep ’25€5.49
€10.29
+87.6%
17.9%€13.69€6.39n/a9
Aug ’25€5.14
€10.14
+97.2%
18.8%€13.90€6.49n/a9
Jul ’25€7.19
€12.85
+78.7%
10.8%€14.86€10.22n/a9
Jun ’25€6.46
€12.85
+98.7%
10.8%€14.86€10.22n/a9
May ’25€6.09
€12.52
+105.6%
11.6%€14.96€10.28n/a9
Apr ’25€6.88
€12.30
+78.8%
12.3%€14.79€10.17n/a8
Mar ’25€8.50
€12.30
+44.7%
12.3%€14.79€10.17n/a8
Feb ’25€8.02
€11.50
+43.4%
11.5%€13.80€10.12n/a7
Jan ’25€5.72
€9.10
+59.1%
18.6%€10.99€5.50n/a8
Dec ’24€4.38
€9.02
+105.8%
18.5%€11.22€5.61n/a7
Nov ’24€3.70
€8.85
+139.3%
21.5%€11.36€5.68€5.487
Oct ’24€3.86
€7.98
+106.8%
22.5%€11.27€5.64€6.107
Sep ’24€3.89
€7.79
+100.2%
24.4%€11.10€5.55€5.496
Aug ’24€3.53
€6.40
+81.4%
21.7%€9.04€4.52€5.146
Jul ’24€3.08
€6.43
+108.7%
21.7%€9.07€4.54€7.196
Jun ’24€3.02
€6.43
+112.8%
21.7%€9.07€4.54€6.466
May ’24€4.08
€6.18
+51.4%
30.8%€9.15€2.74€6.096
Apr ’24€4.51
€6.19
+37.4%
31.7%€9.41€2.82€6.886
Mar ’24€2.72
€5.37
+97.4%
35.4%€7.47€2.80€8.506
Feb ’24€2.62
€5.37
+105.0%
35.4%€7.47€2.80€8.026
Jan ’24€2.39
€5.37
+124.4%
35.4%€7.47€2.80€5.726
Dec ’23€1.62
€4.98
+208.5%
48.3%€7.69€1.54€4.386
Nov ’23€1.49
€4.48
+201.1%
66.4%€9.96€1.00€3.706

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Pharming Group

€498.9m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

7D

-1.0%

1Y

-32.7%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.46

7D

-3.4%

1Y

2.1%

Merck

US$249.2b

Operates as a healthcare company worldwide.

6MK

US$93.10

7D

-1.0%

1Y

-0.1%